Adiposity, Cardiometabolic and Neurocognitive Health Among Ethnic Groups: a Feasibility and Pilot Study

Launched by KING'S COLLEGE HOSPITAL NHS TRUST · May 24, 2024

Keywords

ClinConnect Summary

This clinical trial, called "Adiposity, Cardiometabolic and Neurocognitive Health Among Ethnic Groups," is designed to explore how body fat and other health factors relate to conditions like obesity, liver problems, heart disease, and cognitive issues among different ethnic groups. The study will take place at Kings College Hospital and aims to gather information on participants' body measurements, liver fat, and various health risks, all while considering the participants' backgrounds.

To be eligible for this study, participants must be at least 18 years old and have a body mass index (BMI) of 30 or higher, which indicates obesity. However, those with severe obesity (BMI over 50), recent pregnancies, certain chronic health conditions, or specific medications will not be able to participate. If you join the study, you will come to the hospital for a single visit where your body measurements will be taken, and you'll complete questionnaires about your lifestyle and cognitive health. This study is currently recruiting participants, and it's a great opportunity to contribute to important research that could help improve understanding of health issues related to obesity and ethnicity.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and women aged ≥18 years old
• • Body mass index (BMI) ≥ 30 kg/m2
• Exclusion Criteria:
• • Severe obesity (BMI \> 50 kg/m2)
• • Pregnancy (positive urine hCG) or a recent pregnancy (in the past 6 months)
• • Known active chronic hepatic diseases
• • Known diagnosis of human immunodeficiency virus
• • Pre-established diagnosis of advanced renal failure (estimated Glomerular Filtration Rate (eGFR) \<30 ml/min)
• • Diagnosis of decompensated heart failure
• • History of bariatric surgery
• • Uncontrolled thyroid disease
• • Current use of the following medication: steroids (oral or injections only), weight-loss medication including over-the-counter products, glucagon-like peptide 1 (GLP-1) agonists , Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors